Valued Biopharma Partner,

At Biologics by McKesson, we know that your complex, personalized therapies require customized support tailored to your unique needs. It is a privilege to serve as a partner to you in your product commercialization, collaborating to maximize the potential of your therapy for patients. On that note, I’d like to share with you some organizational changes that we believe will further enhance our services for you and innovation across our business.

Pavlos Pavlidis Biologics Vice President and Chief Operating OfficerFirst, we are creating a new role focused on leading operations across our pharmacy and patient support services, as well as quality and training teams. After a careful and thorough search for both the right industry experience and patient-centered mentality that is essential in our business, I am pleased to announce that Pavlos Pavlidis has joined our team as vice president and chief operating officer.

Pavlos has deep specialty pharmacy operations experience, having previously held roles as vice president and general manager for a large specialty pharmacy and leading a hub organization within a large pharmaceutical manufacturer. Most recently he served as the president and COO of AppianRx and Southside Pharmacy, based in Houston, TX. He is well known in the industry and has developed a reputation for finding innovative solutions to business problems and delivering best-in-class results.

Photograph of Ela LouridoAdditionally, we understand the importance of providing you with a unified, multi-disciplinary team that supports all of your needs—from creation and implementation of a patient-centered launch strategy to supporting your product at steady state and ensuring we drive efficiency and innovation. To that end, I am pleased to announce that Ela Lourido will assume the expanded role of vice president of Biopharma Services.

In addition to her current responsibility of leading business development, she will also lead our account management, launch excellence and client execution teams. This organizational change will establish Ela as the single point of executive leadership overseeing all of our biopharma facing services—beginning with award of business, into product commercialization and beyond.

Ela has over fifteen years’ experience in the specialty pharmacy space, focusing on oncology and rare diseases. She will continue to leverage her specialty pharmacy expertise to optimize your commercial strategy, particularly in the areas of:

  • Program design for new therapies
  • Patient access services
  • Integrated specialty pharmacy and hub solutions
  • Contract structures and data specifications
  • Operational excellence and brand growth
  • technology solutions

I hope you are as excited about this realignment as we are. While we are continuously evaluating ways to strengthen our offerings, our intention is to keep you at the center of our solution, providing a dedicated biopharma team to support your product throughout its lifecycle. We look forward to the opportunity to better meet your needs and provide you with continuous collaboration and communication as we move forward.

Warmest regards,

Brandon Tom signature

Brandon Tom
Vice President/General Manager
Biologics by McKesson